Evidence map›Paper›PMID 42591545›Full record

ArticleTranslational cancer research2026

Junling Zhu, Xujie Tang, Qianru Zhu, Sen Jiang

Abstract read
In one paragraph

Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Junling Zhu *Department of Traditional Chinese Medicine, Ningbo No. 2 Hospital, Wenzhou Medical University, Ningbo, China.
Xujie Tang *Department of Traditional Chinese Medicine, Ningbo No. 2 Hospital, Wenzhou Medical University, Ningbo, China.
Qianru ZhuDepartment of Traditional Chinese Medicine, Ningbo No. 2 Hospital, Wenzhou Medical University, Ningbo, China.
Sen JiangDepartment of Emergency, Ningbo No. 2 Hospital, Wenzhou Medical University, Ningbo, China.ORCID https://orcid.org/0009-0001-2941-8350

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Prognostic stratification in hepatocellular carcinoma (HCC) remains difficult because standard staging systems do not fully capture the biological heterogeneity of the disease. We hypothesized that developmental regulators could provide a biologically relevant framework for prioritizing prognostic markers. Methods: RNA sequencing (RNA-seq) and clinical data from The Cancer Genome Atlas liver hepatocellular carcinoma (TCGA-LIHC) cohort were analyzed. Tumor Results: Among the screened developmental regulator-related genes, Conclusions:

Indexed as

biomarkerHepatocellular carcinoma (HCC)HOXD9prognosisThe Cancer Genome Atlas liver hepatocellular carcinoma (TCGA-LIHC)

Identifiers

PMID42591545
PMCPMC13461845

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.